コンテンツへスキップ
Merck

主要文書

すべての文書を表示

676492

MAZ51

≥95% (HPLC), solid, VEGFR3 kinase inhibitor, Calbiochem®

別名:

VEGFR3 Kinase Inhibitor, MAZ51, MAZ51, 3-(4-Dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one, Vascular Endothelial Growth Factor Receptor 3 Kinase Inhibitor, VEGFR Tyrosine Kinase Inhibitor XVI, VEGFR3 Kinase Inhibitor I

ログインで組織・契約価格をご覧ください。

サイズを選択してください

表示を変更する

この商品について

実験式（ヒル表記法）:
C21H18N2O
CAS番号:
163655-37-6
分子量:
314.38
MDL number:
MFCD04036983
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥95% (HPLC)
Form:
solid
Quality level:
100
Storage condition:
OK to freeze, protect from light
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします

製品名

VEGFR3 Kinase Inhibitor, MAZ51, The VEGFR3 Kinase Inhibitor, MAZ51, also referenced under CAS 163655-37-6, controls the biological activity of VEGFR3 Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

Quality Level

100

assay

≥95% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

color

red

solubility

DMSO: 10 mg/mL

shipped in

ambient

storage temp.

2-8°C

SMILES string

N1c2c(cccc2)C(=Cc3c4c(c(cc3)N(C)C)cccc4)C1=O

InChI

1S/C21H18N2O/c1-23(2)20-12-11-14(15-7-3-4-9-17(15)20)13-18-16-8-5-6-10-19(16)22-21(18)24/h3-13H,1-2H3,(H,22,24)

InChI key

VFCXONOPGCDDBQ-UHFFFAOYSA-N

General description

A cell-permeable 3-substituted indolin-2-one compound that acts as a reversible and ATP-competitive VEGF receptor tyrosine kinase inhibitor. At low concentration (≤5 µM), it specifically blocks VEGF-C- (Cat. No. 676476) and VEGF-D- (Cat. No. 676471) induced phosphorylation of VEGFR-3, but not VEGFR-2, in PAE cells. It partially blocks VEGFR-2 phosphorylation only at higher concentrations (50 µM). This differential blocker may be useful for inhibiting lymphangiogenesis-dependent pathological process such as tumor metastasis. Not available for sale in Germany.
A cell-permeable, 3-substituted, indolin-2-one compound that acts as a reversible and ATP-competitive inhibitor of VEGF receptor tyrosine kinase. At low concentrations (5 µM), reported to specifically block VEGF-C and VEGF-D-induced phosphorylation of VEGFR-3, but not VEGFR-2, in PAE cells. Reported to partially block VEGFR-2 phosphorylation only at higher concentrations (50 µM). This differential inhibition may be useful for controlling lymphangiogenesis-dependent tumor metastasis and could, therefore, be of clinical significance for cancer therapy studies.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
VEGF receptor tyrosine kinase
Product competes with ATP.
Reversible: yes
Target IC50: At low concentration (≤5 µM), it specifically blocks VEGF-C- and VEGF-D-induced phosphorylation of VEGFR-3, but not VEGFR-2, in PAE cells.

Packaging

Packaged under inert gas

Other Notes

Kirkin, V., et al. 2001. Eur. J. Biochem.268, 5530

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

保管分類

11 - Combustible Solids

wgk

WGK 3

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

676492-1.1ML: + 676492-5UNMG: + 676492-MG: + 676492-10MG:

jan

試験成績書（COA）

製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Pu-Hong Zhang et al.
JCI insight, 9(1) (2023-11-17)
The lymphatic vasculature is the natural pathway for the resolution of inflammation, yet the role of pulmonary lymphatic drainage function in sepsis-induced acute respiratory distress syndrome (ARDS) remains poorly characterized. In this study, indocyanine green-near infrared lymphatic living imaging was
Jinman Chen et al.
Nature communications, 11(1), 3159-3159 (2020-06-24)
Extravasated erythrocytes in cerebrospinal fluid (CSF) critically contribute to the pathogenesis of subarachnoid hemorrhage (SAH). Meningeal lymphatics have been reported to drain macromolecules and immune cells from CSF into cervical lymph nodes (CLNs). However, whether meningeal lymphatics are involved in
Raj Kumar et al.
Cell death & disease, 11(5), 325-325 (2020-05-10)
Pathological retinal neovascularization is the most common cause of vision loss. PKCθ has been shown to play a role in type 2 diabetes, which is linked to retinal neovascularization. Based on these clues, we have studied the role of PKCθ

グローバルトレードアイテム番号

カタログ番号GTIN
676492-10MGCN04055977183689